This study aims to find a better way to detect gynecologic cancers, which include cancers of the uterus, ovaries, and cervix, by using special markers in DNA called Methylated DNA Markers (MDMs) and high-risk human papilloma virus (HR-HPV). These markers can be detected in samples from vaginal fluid or blood plasma. Early detection of these cancers can increase the chance of a cure and reduce the need for tough surgeries, radiation, or chemotherapy. **Key Points:** - **Participation involves sample collection** from vaginal fluid or blood, depending on the type of cancer being studied. - **Participants may need to meet specific age and health criteria**, such as having abnormal uterine bleeding or a history of certain conditions. - **There are several exclusion criteria**, including recent surgeries, pregnancy, or recent cancer treatments, which would prevent participation. The study seeks to develop a less invasive test to help determine whether bleeding is due to cancer or a non-cancerous condition. If you meet the criteria and want to join, you should be prepared for some medical evaluations and possibly some minor risks related to sample collection.